Linopristin/flopristin
Alternative Names: NXL-103; RPR 202868/RPR 132552; XRP 2868Latest Information Update: 03 Sep 2015
At a glance
- Originator sanofi-aventis
- Developer AstraZeneca
- Class Antibacterials; Streptogramins
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Community-acquired pneumonia; Skin and soft tissue infections
Most Recent Events
- 03 Sep 2015 No recent reports on development identified - Phase-II for Community-acquired pneumonia in Ukraine, Romania, Poland, Estonia, Peru, Croatia, Germany, South Africa and Chile (PO)
- 03 Sep 2015 No recent reports on development identified - Phase-II for Skin and soft tissue infections in Guatemala and USA (PO)
- 06 Nov 2009 Phase-II clinical trials in Skin and soft tissue infections in USA (PO)